Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367991 · ClinicalTrials.gov registry record · Phase 2
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00367991 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 44 participants.
The verdict
NCT00367991, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Patients with heart attacks are treated with medicines to reduce the clotting action of platelets. This study is trying to determine whether erythropoietin alters the clotting action of platelets in patients receiving anti-platelet medicines. It is important to understand the effects of erythropoietin on platelets since preliminary studies in animals suggest that erythropoietin may protect the heart from damage during a heart attack.
Interventions
- DRUG Placebo
- DRUG Recombinant human erythropoietin alfa (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00367991
The ClinicalTrials.gov registry entry for NCT00367991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00367991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00367991 about?
NCT00367991 is a clinical study titled "Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction". The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Patients with heart attacks are treated with medicines to reduce the clotting action of platelets. This study is trying to determine whether erythropoietin alters ...
What is the current status of trial NCT00367991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2006-11. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00367991?
The interventions under investigation include: Placebo (DRUG), Recombinant human erythropoietin alfa (drug) (DRUG).
Who is sponsoring clinical trial NCT00367991?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.